BioVaxys Technology (TSE:BIOV) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
BioVaxys Technology Corp. has been granted a U.S. patent for a novel low-dose vaccine delivery system that enhances antibody immune response, with promising applications in various diseases. The proprietary DPX™ technology allows for a potent and sustained immune response, which has shown encouraging results in clinical studies for RSV, with potential for other diseases.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
